

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: World Journal of Hepatology

Manuscript NO: 76855

Title: The HCV burden: treating and educating people without prejudice

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 06084005

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: Spain

Author's Country/Territory: Italy

Manuscript submission date: 2022-04-03

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-04-03 14:33

Reviewer performed review: 2022-04-03 14:47

Review time: 1 Hour

Scientific quality	[] Grade A: Excellent [Y] Grade B: Very good [] Grade C: Good [] Grade D: Fair [] Grade E: Do not publish
Language quality	 [] Grade A: Priority publishing [Y] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	 [] Accept (High priority) [Y] Accept (General priority) [] Minor revision [] Major revision [] Rejection
Re-review	[] Yes [Y] No
Peer-reviewer	Peer-Review: [] Anonymous [Y] Onymous



Baishideng **Publishing**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

statements

Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

I think this is an important topic for research. The manuscript is interesting, adheres to all journal standards and covers some important aspects. There are minor linguistic issues throughout the manuscript, which can possibly be solved easily by a native speaker. I think this is a very interesting research to publish.



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: World Journal of Hepatology

Manuscript NO: 76855

Title: The HCV burden: treating and educating people without prejudice

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 02528485

Position: Peer Reviewer

Academic degree: PhD

Professional title: Professor

Reviewer's Country/Territory: Taiwan

Author's Country/Territory: Italy

Manuscript submission date: 2022-04-03

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-04-04 08:18

Reviewer performed review: 2022-04-07 05:47

Review time: 2 Days and 21 Hours

Scientific quality	[] Grade A: Excellent [] Grade B: Very good [Y] Grade C: Good [] Grade D: Fair [] Grade E: Do not publish
Language quality	 [] Grade A: Priority publishing [Y] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	 [] Accept (High priority) [] Accept (General priority) [Y] Minor revision [] Major revision [] Rejection
Re-review	[Y]Yes []No
Peer-reviewer	Peer-Review: [Y] Anonymous [] Onymous



Baishideng **Publishing**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA Telephone: +1-925-399-1568 E-mail: bpgoffice@wjgnet.com https://www.wjgnet.com

statements

Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

This study intends to describe the impact of our HCV-dedicated service for substance use disorder (SSUD) with regard to PWIDs receiving anti-HCV therapy. Several suggestions: 1. Page 8, please add references or website after the following sentences: [Indications for DAA therapy followed the WHO criteria] ; [The HCV genotype was assessed prior to the start of treatment]; [the stage of liver disease was evaluated using transient elastography]; [The treatment regimen was based on the standard 12-week oral schedule with Sofosbuvir/ Velpatasvir or an 8-week oral Glecaprevir/Pibrentasvir regimen]. 2. Page 10, please check [Thirty-eight out of 40 recruited patients were receiving opioid agonist maintenance therapy at study inclusion, whilst another 4 had just completed the treatment.] 38+4=42 not 40?